Pharma News

Scientists from the University of Exeter found that Consumption of high nitrate beetroot juice improves both sprint performance and decision-making in Rugby players. The study is published in the European Journal of Applied Physiology.

Jubilant Life Sciences Ltd, an integrated global pharmaceuticals company, has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (FDA) for zolmitriptan orally disintegrating tablets, 2.5 mg and 5 mg the generic version of Zomig-ZMT (AstraZeneca), which is used for acute treatment of migraine headaches in adults.

A team of researchers were able to predict whether worms would live long by measuring how they move towards an appealing, food-like scent. The study will be published in the Journal eLife.

Drinking carbonated beverages is associated with increased risk of fatal cardiovascular disease, a new Japanese study has found. The study in nearly 800,000 patients in Japan suggests that limiting consumption of carbonated beverages may be beneficial for health.

New research has found that practicing yoga improves physical and mental wellbeing of people living with arthritis. The findings were published in the Journal of Rheumatology.

In Europe and Asia  drug currently used for treating gallstone-related spasms has been found effective in preventing the onset of Type-1 diabetes in mice. Researchers believe that a similar treatment may be effective in preventing the autoimmune disorder in humans too. The study was published in the Journal of Clinical Investigation.

A team of US researchers has developed 3D-printed guide that regrow both the sensory and motor functions of complex nerves after injury. The study was published in the journal Advanced Functional Materials.

[adsense:336x280:8701650588]

Sun Pharmaceutical Industries Ltd. and Strides Arcolab Ltd. have entered into a definitive agreement related to erstwhile Ranbaxy’s ‘Solus’ and ‘Solus Care’ divisions operating in the central nervous system (CNS) segment in India.

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company's (NYSE: LLY) Jardiance® (empagliflozin) significantly reduced the risk of the combined endpoint of cardiovascular (CV) death, non-fatal heart attack or non-fatal stroke by 14 percent when added to standard of care in patients with type 2 diabetes (T2D) at high risk of CV events. There was a 38 percent reduction in CV death, with no significant difference in the risk of non-fatal heart attack or non-fatal stroke.